Tms 005 c

Manufactured by Merck Group

TMS-005-C is a laboratory equipment product manufactured by Merck Group. It is designed to perform a core function, but a detailed description cannot be provided while maintaining an unbiased and factual approach without extrapolation or interpretation.

Automatically generated - may contain errors

Lab products found in correlation

Lm r1637, by Biosera (3 mentions) Fb 1001h, by Biosera (3 mentions) Tms 002 c, by Merck Group (3 mentions) Tms 001 c, by Merck Group (3 mentions) Es 007 e, by Merck Group (3 mentions) A5955, by Merck Group (3 mentions) Crl 2836, by American Type Culture Collection (1 mentions)

3 protocols using tms 005 c

Breast Cancer and Fibrosarcoma Cell Culture

Check if the same lab product or an alternative is used in the 5 most similar protocols

The 4T1 (ATCC CRL-2539) and E0771 (94A001,
CH3 BioSystems) breast adenocarcinoma cell lines were maintained in
Dulbecco’s modified Eagle medium (DMEM, LM-D1109, Biosera)
and Roswell Park Memorial Institute medium (RPMI-1640, LM-R1637, Biosera),
respectively, and supplemented with 10% fetal bovine serum (FBS, FB-1001H,
Biosera) and 1% antibiotics (A5955, Sigma). Cell lines were preserved
in 5% CO₂ at 37 °C. MCA205 fibrosarcoma cells (SCC173,
Millipore) were cultured in RPMI-1640 (LM-R1637, Biosera) containing
2 mM l-glutamine (TMS-002-C, Sigma-Aldrich), 1 mM sodium
pyruvate (TMS-005-C, Sigma-Aldrich), 10% FBS (FB-1001H, Biosera),
1× nonessential amino acids (TMS-001-C, Sigma-Aldrich), 1% antibiotics
(A5955, Sigma), and 1× β-mercaptoethanol (ES-007-E, Sigma).

Mpekris F., Papaphilippou P.C., Panagi M., Voutouri C., Michael C., Charalambous A., Marinov Dinev M., Katsioloudi A., Prokopi-Demetriades M., Anayiotos A., Cabral H., Krasia-Christoforou T, & Stylianopoulos T. (2023). Pirfenidone-Loaded Polymeric Micelles as an Effective Mechanotherapeutic to Potentiate Immunotherapy in Mouse Tumor Models. ACS Nano, 17(24), 24654-24667.

+ Open protocol

+ Expand

Murine Breast Cancer and Fibrosarcoma Cell Culture

Check if the same lab product or an alternative is used in the 5 most similar protocols

4T1 (ATCC CRL-2539) and E0771 (94A001, CH3 BioSystems) mouse breast adenocarcinoma cell lines were purchased form ATCC and CH3 BioSystems, respectively. The cells were maintained at 37 °C/ 5% CO₂ in Roswell Park Memorial Institute medium (RPMI-1640, LM-R1637, biosera) supplemented with 10% fetal bovine serum (FBS, FB-1001H, biosera) and 1% antibiotics (A5955, Sigma). The MCA205, mouse fibrosarcoma cell line was purchased from Millipore (SCC173, Millipore) and cultured in expansion medium consisting of RPMI-1640 (LM-R1637, biosera) supplemented with 2 mM L-glutamine (TMS-002-C, Sigma), 1 mM sodium pyruvate (TMS-005-C, Sigma), 10 % fetal bovine serum (FBS, FB-1001H, biosera), 1x non-essential amino acids (TMS-001-C, Sigma), 1% antibiotics (A5955, Sigma) and 1x β-mercaptoethanol (ES-007-E, Sigma). MCA205 cells were also maintained at 37 °C/ 5 % CO₂.

Panagi M., Mpekris F., Chen P., Voutouri C., Nakagawa Y., Martin J.D., Hiroi T., Hashimoto H., Demetriou P., Pierides C., Samuel R., Stylianou A., Michael C., Fukushima S., Georgiou P., Papageorgis P., Papaphilippou P.C., Koumas L., Costeas P., Ishii G., Kojima M., Kataoka K., Cabral H, & Stylianopoulos T. (2022). Polymeric micelles effectively reprogram the tumor microenvironment to potentiate nano-immunotherapy in mouse breast cancer models. Nature Communications, 13, 7165.

+ Open protocol

+ Expand

Culturing Fibrosarcoma and Osteosarcoma Cells

Check if the same lab product or an alternative is used in the 5 most similar protocols

MCA205 fibrosarcoma cells (SCC173, Millipore) were cultured in RPMI-1640 (LM-R1637, biosera) containing 2 mM L-glutamine (TMS-002-C, Sigma-Aldrich), 1 mM sodium pyruvate (TMS-005-C, Sigma-Aldrich), 10 % fetal bovine serum (FBS, FB-1001H, biosera), 1x non-essential amino acids (TMS-001-C, Sigma-Aldrich), 1 % antibiotics (A5955, Sigma) and 1x β-mercaptoethanol (ES-007-E, Sigma). K7M2-WT osteosarcoma cells (CRL2836, ATCC) were cultured in DMEM (LM-S2041, biosera) containing with 10 % FBS and 1 % antibiotics. Cells were incubated at 37 ºC/ 5 % CO₂.

Mpekris F., Panagi M., Charalambous A., Voutouri C., Michael C., Papoui A, & Stylianopoulos T. (2024). A synergistic approach for modulating the tumor microenvironment to enhance nano-immunotherapy in sarcomas. Neoplasia (New York, N.Y.), 51, 100990.

+ Open protocol

+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Revolutionizing how scientists
search and build protocols!